Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYB
REST API REST API
Homo sapiens
MYB is differentially expressed in 303 experiments: 124 organism parts: bone marrow, thymus, ... (122 more);, 196 disease states: normal, prostate carcinoma, ... (194 more);, 111 cell types 420 cell lines 37 compound treatments and 88 other conditions.
Synonyms c-myb
Orthologs D4AAU2_RAT (Rattus norvegicus)   Myb (Mus musculus)   ENSCING00000002687 (Ciona intestinalis)   MYB (Bos taurus)   MYB (Gallus gallus)   BAS1 (Saccharomyces cerevisiae)   cmyb (Danio rerio)   Myb (Drosophila melanogaster)   myb (Xenopus laevis)   Q9XT66_CANFA (Canis familiaris)   (Compare orthologs)
InterPro Term Myb_DNA-bd, SANT_DNA-bd, MYB-like, C-myb_C, Tscrpt_reg_Wos2-domain
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, positive regulation of histone H3-K4 methylation, embryonic digestive tract development, transcription, DNA-dependent, blood coagulation, nuclear matrix, positive regulation of transcription from RNA polymerase II promoter, G1/S transition of mitotic cell cycle, nucleus, regulation of gene expression, chromatin remodeling, calcium ion transport, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, in utero embryonic development, sequence-specific DNA binding transcription factor activity, positive regulation of histone H3-K9 methylation, positive regulation of T-helper cell differentiation
UniProt Accession Q708J0, Q708E6, Q708E8, Q708E9, Q708E3, Q708E5, Q708E1, Q9UMI7, Q5THS5, Q5THS6, Q5THS4, P10242, E9PNL6, E9PNH6, E9PNA4, E9PMZ0, E9PN92, E9PMQ0, E9PN43, E9PPR4, E9PPL8, E9PP87, E9PRS2, E9PQQ2, E9PI07, E9PIW4, E9PJ96, E9PJF1, E9PJT2, E9PKZ3, E9PLN0, E9PLZ5, F8W8G5
Search EB-eye ENSG00000118513
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
SW480
4
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
MCF-7
3
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081
HL-60
1
3
E-GEOD-5258, E-MTAB-37, E-GEOD-96, E-GEOD-24147
A549
2
E-GEOD-3202, E-GEOD-6013
Jurkat
2
E-GEOD-1880, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
414 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (52 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-GEOD-1460, E-MEXP-1327, E-MEXP-2034, E-GEOD-10797
CD34+
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
white blood cell
1
E-GEOD-2006
mononuclear cell
1
E-GEOD-6053
chondrocyte
1
E-TABM-130
105 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-MTAB-680, ... (58 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-MEXP-1327, E-MEXP-2034, E-MTAB-37, E-MTAB-62 ... (5 experiments)
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
acute promyelocytic leukemia
1
3
E-MTAB-62, E-GEOD-96, E-GEOD-995, E-GEOD-1729
Wilms tumor
2
E-MTAB-37, E-GEOD-2712
chronic myelogenous leukemia
2
E-MTAB-37, E-MTAB-62
squamous cell carcinoma
2
E-MTAB-37, E-MTAB-62
190 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-TABM-782, E-GEOD-5824, ... (30 experiments)

Factor Value U/D Experiments
none
5
9
E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, E-MEXP-1958, ... (14 experiments)
glutamine
2
E-MEXP-941, E-MEXP-1335
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
AMP
1
1
E-MEXP-2285
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
bacterial endotoxin
1
E-GEOD-3284
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-GEOD-860, E-GEOD-2191, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-2509, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-TABM-1029, E-GEOD-3494, E-GEOD-21750, E-TABM-868, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-3720, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-22152, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.477 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM